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EDITORIAL
Revisiting the approach 
to patients with stable 
ischaemic symptoms
cularisation by angioplasty and stenting. In most cases, the vessel 
can be successfully revascularised and the cardiologist con-
fidently congratulates the patient with the assurance that a 
serious future cardiovascular event has been avoided.
Despite the visually satisfying effect of this approach, it is 
appropriate to question whether the intervention improved the 
patient’s quality of life and chances of survival. This overview 
examines the results of the clinical trials in patients with stable 
ischaemic symptoms that have compared revascularisation with 
medical treatment.
COMPARISON OF CORONARY BYPASS 
SURGERY TO MEDICAL TREATMENT
The Coronary Artery Surgery Study(3) which was performed 
between 1975 and 1979 included 780 patients with stable 
coronary artery disease. These patients were assigned to either 
coronary bypass surgery or medical management. Excellent 
survival was reported in both groups whether single vessel, 
double vessel or triple vessel coronary disease was present. The 
authors concluded that patients like those enrolled in the trial 
could safely defer bypass surgery until symptoms worsened 
to the point that surgical palliation was required. Subgroup 
analysis(4) showed that survival was improved by surgical revas-
cularisation in patients with left main stem stenosis of 60% or 
greater, in particular those with moderate to severe impair-
ment of left ventricular function. The Veterans Administra-
tion cooperative study of surgery for coronary arterial occlusive 
disease(5) drew similar conclusions. In their second interim 
report the European Coronary Surgery Study Group(6) found 
that surgical revascularisation conferred significantly better 
5-year survival than those who were not operated. The sub-
groups of patients with left main disease and 3 vessel disease 
derived the greatest benefit. Consequently, even before the 
emergence of frequently performed percutaneous revas-
cularisation, there was evidence that in many cases the relief of 
coronary obstruction did not confer an overall survival benefit.
COMPARISON OF PERCUTANEOUS 
INTERVENTION OR CORONARY BYPASS 
SURGERY TO MEDICAL TREATMENT
The COURAGE trial(7) was published in 2007. The result was 
widely criticised for the intense selection criteria applied which 
The 2019 European Society of Cardiology Guideline on chronic 
coronary syndromes(1) defines coronary artery disease (CAD) 
as the result of atherosclerotic plaque accumulation in the epi-
cardial coronary arteries. The disease is chronic and progressive, 
characterised by long quiescent periods punctuated by acute 
exacerbations. The chronic coronary syndromes are categorised 
as (i) stable angina or dyspnoea, (ii) new-onset heart failure or 
left ventricular dysfunction and suspected CAD, (iii) stable 
symptomatic or asymptomatic patients less than 1 year after 
acute coronary syndrome or revascularisation, (iv) stable 
symptomatic or asymptomatic patients more than 1 year after 
diagnosis or revascularisation, (v) patients with vasospastic or 
microvascular angina, and (vi) asymptomatic patients whose 
CAD is detected at screening. 
Since the introduction of coronary angioplasty by Dr Andreas 
Gruntzig(2) in the late 1970s, despite his advocacy of a cautious 
and conservative approach to coronary intervention, cardio-
logists seized on angioplasty and then later stents to treat 
patients with all manner of obstructed coronary arteries. A 
familiar clinical scenario would be the middle-aged smoker 
with dyslipidaemia who complains of angina pectoris twice a 
month and is shown to have ST segment depression in the 
ECG. Commonly, this patient will be offered coronary angio-
graphy and if a stenosis is found, the cardiologist, influenced by 
the “oculostenotic reflex” will proceed immediately to revas-
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resulted in only 6.4% of the 35 589 patients assessed for the 
trial being included. These were patients with stable angina 
who were randomised to either percutaneous intervention or 
medical therapy. Approximately 10% of patients were lost to 
follow-up during the trial. Accepting these reservations, over 
7 years of follow-up no difference could be shown when PCI 
was compared to medical therapy whether death from any 
cause and myocardial infarction, overall survival, survival free of 
acute coronary syndrome or survival free of myocardial infarc-
tion was considered. 
Two years after the COURAGE trial, the BARI 2D Study 
Group(8) reported on 2 368 patients with type II diabetes 
treated on insulin or oral drugs who had coronary artery 
disease proven on angiography. Patients were included if they 
had a positive exercise stress test with a coronary stenosis 
greater than 50% or alternately had classical angina with a 
coronary stenosis greater than 70%. Based upon the extent of 
their coronary disease, approximately one third of patients 
were considered suitable for coronary bypass surgery while the 
remainder were deemed suitable for percutaneous coronary 
intervention. Half the patients suitable for coronary bypass 
surgery and half the patients suitable for percutaneous inter-
vention were then randomised to receive initial medical therapy 
without revascularisation. These patients were followed for 5 
years. During this period 42% of patients initially receiving only 
medical treatment underwent revascularisation. At 5 years 
there was no difference in the survival or the incidence of 
major cardiovascular events between the patients initially 
treated medically and those who had revascularisation in 
addition to medical treatment, whether they had had per-
cutaneous coronary intervention or coronary bypass surgery. 
A higher mortality was noted in the bypass surgery group 
amongst which there was a higher incidence of triple vessel 
disease, proximal left anterior descending stenoses and chronic 
total occlusions. The conclusion drawn from this study was that 
a strategy of prompt coronary revascularisation in patients 
treated with intensive medical therapy for diabetes and stable 
ischaemic heart disease did not significantly reduce the rate of 
death from any cause or of major cardiovascular events. How-
ever, a later analysis of the trial(9) that quantified the severity of 
coronary disease according to the baseline SYNTAX score(10) 
found that while percutaneous coronary intervention had no 
significant impact on long-term outcomes in those with a higher 
score, coronary bypass surgery plus medical therapy had 
resulted in an almost 50% reduction in the incidence of death, 
myocardial infarction and stroke when compared to initial 
medical treatment only. The authors concluded that among 
patients with diabetes and stable ischaemic heart disease, higher 
SYNTAX scores predicted higher rates of major cardiovascular 
events and, when compared to medical therapy, were asso-
ciated with more favourable outcomes in those patients suitable 
for revascularisation by coronary bypass surgery.
In 2014, a large network meta-analysis of more than 90 trials 
that had compared revascularisation to medical treatment 
alone was published.(11) The authors reported significant reduc-
tions in mortality (20%), myocardial infarction (21%) and the 
need for revascularisation (84%) with coronary bypass surgery 
when compared to medical treatment. The trials of percuta-
neous transluminal revascularisation that were included ranged 
from early studies with balloon angioplasty through bare metal 
stents to the newer generation drug-eluting stents. Though 
there were progressive reductions in the need for revascu-
larisation with the development of improved stent technology 
(56% - 73%), overall there was no mortality benefit from per-
cutaneous intervention nor was there a significant reduction in 
myocardial infarction. Considering only the newer generation 
drug-eluting stents (everolimus and zatarolimus), there was a 
reduction in mortality (25%) compared to medical treatment. 
This analysis did not evaluate the extent of coronary artery 
disease present in these patients nor was the average period of 
follow-up stated.
ISCHEMIA AND ISCHEMIA-CKD
The International Study of Comparative Health Effectiveness 
with Medical And Invasive Approaches (ISCHEMIA) trial(12) 
compared routine invasive therapy plus optimal medical therapy 
to optimal medical therapy alone in stable patients with 
moderate-to-severe ischaemia demonstrated on non-invasive 
stress testing with a nuclear study, echocardiographic stress 
testing, cardiac MRI or treadmill exercise testing. 5 179 patients 
were randomised. The frequency of the patients’ angina was 
daily or weekly in 22%, several times a month in 44% and 34% 
did not experience angina. The majority of patients underwent 
CT coronary angiography to exclude the presence of left main 
stem stenosis. Patients with recent myocardial infarction, an 
ejection fraction below 35%, NYHA class III or IV heart failure, 
unacceptable levels of baseline angina and those who had 
undergone revascularisation within the last year were also 
excluded. Patients with chronic kidney injury were assigned to 
a separate trial. Follow-up was for 3.3 years. In the invasive arm 
96% of patients underwent cardiac catheterisation and 80% 
were revascularised. Over the trial period 28% on optimal 
medical therapy only were judged to be therapeutic failures and 
underwent coronary angiography. 23% of the group were 
revascularised. The primary endpoint of the trial was a com-
posite of cardiovascular death, myocardial infarction, resus-
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late outcomes continue to diverge to the end of follow-up. A 
longer follow-up of these patients may show the emergence 
of a significant difference in favour of the invasive approach 
(Doshi P). The ISCHEMIA trial supports either an invasive or 
conservative approach patients with stable disease who have 
either no symptoms or mild symptoms that can be controlled 
with medication and moderate-to-severe ischaemia (Stone G).
ORBITA
The consistency of the findings in these trials raises the ques-
tion of what benefit percutaneous intervention offers in patients 
who have chronic coronary syndrome without disabling 
symptoms and in whom left main stem stenosis has been 
excluded. Of course, it is possible that patients with a poor 
prognosis may be overlooked when a conservative strategy 
with optimal medical therapy is adopted. The significance of a 
coronary stenosis seen an angiogram has been open to ques-
tion for many years. The measurement of the Fractional Flow 
Rate offers a means to assess the functional significance of 
an observed stenosis.(15) Several studies have demonstrated 
that the importance of the stenosis is frequently overestimated 
or underestimated when assessed on an angiogram. Further-
more, the safety of not treating what appears to be a significant 
stenosis on angiography when the FFR is within the normal 
range has been demonstrated repeatedly. Thus, the European 
Society of Cardiology 2019 Guideline on Chronic Coronary 
Syndromes recommends that the FFR should be measured in 
all vessels less than 90% stenosed and treating only those with 
an FFR below 0.80.(1) 
In the ISCHEMIA trial FFR could be used when available and 
appropriate. However, in the smaller ORBITA trial(16) of only 
200 patients, FFR was employed universally. These patients 
had Canadian Cardiovascular Society class II or III angina. 
After a period during which medical therapy was optimised, 
patients underwent assessment of their functional capacity 
with cardio-pulmonary exercise testing, myocardial ischaemic 
burden with dobutamine stress echocardiography, and a quality 
of life assessment. Every patient underwent coronary angio-
graphy. All had significant single vessel coronary artery stenosis 
(mainly left anterior descending) as judged visually from the 
angiogram. Double-blinded invasive physiological assessment 
of fractional flow reserve (FFR) and instantaneous wave-free 
ratio (iFR) was done. The mean FFR was 0.69, consistent with 
haemodynamically significant stenoses. Uniquely these patients 
were randomised to revascularisation with implantation of a 
drug-eluting stent or to a sham procedure. Blinding was 
maintained throughout the trial by sedating the patients during 
the intervention. All patients received guideline-directed 
citated cardiac arrest, and hospitalisation for unstable angina or 
heart failure. The frequency of the primary endpoint was 13.3% 
in the invasive group and 15.5% in those on optimal medical 
therapy alone. The difference was not statistically significant. 
There was a threefold increase in peri-procedural myocardial 
infarction and a one third reduction in spontaneous myocar-
dial infarction in the invasive arm. The Kaplan-Meier curves 
demonstrated a 2% increase in harm in the first 6 months in the 
invasive group and a 2% greater benefit at 4 years. The quality 
of life was improved in the invasive group only in those patients 
with angina.
The parallel ISCHEMIA-CKD trial(13) enrolled 777 patients 
with chronic kidney injury defined as an eGFR less than 30. The 
design was essentially like that of the main ISCHEMIA trial. 
The 3-year mortality in these patients was 25%. Once again, 
there was no difference in outcome when invasive therapy plus 
optimal medical therapy was compared to optimal medical 
therapy alone. There were no substantial or sustained benefits 
regarding angina-related health status with an initially invasive 
strategy as compared with a conservative strategy.(14) The 
trialists concluded that intervention in patients with chronic 
kidney disease should be reserved for those who require relief 
of symptoms.
The following are the opinions of several experts regarding the 
impact of ISCHEMIA. These results were achieved using the 
very best medical therapy with the latest treatment targets, 
the best cobalt-chromium limus-eluting thin-strut stents, deriva-
tives that reduce re-stenosis, and a modern-day approach to 
coronary bypass surgery (Antman E). ISCHEMIA proved that 
revascularisation does not have a marked effect on outcome 
(de Lemos J) and indicates that not every patient with 
moderate-to-severe ischaemia needs to go to the cath lab right 
away nor that not every blockage needs to have a stent right 
away (Nallamothu BJ). Presently most patients with chronic 
coronary syndrome land up in the cath lab where the cardi-
ologist is expected to fix them (Mehran R). Stress tests will still 
be necessary to confirm that symptoms are arising from 
ischaemia (Poppas A) but rather than performing several stress 
tests, it is more important to rule out left main stem stenosis 
with CT coronary angiography (Mehran R). This change in 
emphasis in non-invasive testing is predicted to have major 
effects on future practice (de Lemos J). One would be 
comfortable advising patients not to undergo the invasive 
strategy if their angina were absent or controlled or tolerated. 
There should be no obligation to send them to the cath lab 
(Jacobs A). Naturally, interventionalists weighed in with critical 
comment, pointing out that the early difference in the trial was 
driven by periprocedural myocardial infarction whereas the 

















moreover biologically plausible. This view of the pathophysi-
ology ignores the possible contributions of symptoms arising 
from a non-target stenosis and/or from microvascular disease. 
While the short duration of the ORBITA trial cannot answer 
questions about potential differences in longer term outcomes 
of stenting added to medical therapy versus medical therapy 
alone, it does provide clear insight into a potent, previously 
unexplored placebo effect in patients who undergo stenting for 
stable angina. 
CONCLUSIONS
The trials and analyses referred to here include only those 
patients with chronic coronary syndrome and exclude those 
with current or recent acute coronary syndromes, left main 
secondary preventive treatment and similar amounts of 
antianginal therapy. The guideline-directed therapeutic targets 
for blood pressure and LDL cholesterol were met. Patients 
were followed for 6 weeks and then resubmitted to the tests 
of their functional capacity, ischaemic burden and quality of 
life. Although there was a significant improvement in the peak 
stress wall motion score in the stented group, no difference 
was found in the Duke treadmill score, the trial’s primary 
endpoint, between the 2 groups nor in angina or the degree of 
ST segment depression after exercise. 
The ORBITA trial challenges the concept of a simple linkage 
between angina pectoris and significant coronary stenosis which 
is so frequently held by clinicians and their patients and which is 
Symptoms suggesting angina
Risk factor and clinical assessment
Functional test for ischaemia + Rx OMT
NegativePositive
Yes (5%) No


















FIGURE 1: Proposed algorithm for the investigation and treatment of patients with chronic coronary syndrome following 
the ISCHEMIA study.
Abbreviations: Ex Stress Test = exercise stress test, MPI = myocardial perfusion imaging, stress echo = echocardiographic stress test, 
Rx = treat with, OMT = optimal medical therapy, ACE/ARB = angiotensin converting enzyme inhibitor or angiotensin receptor blocker, 
CTCA = computed tomographic coronary angiogram, LM = left main stem coronary artery, PCI/CABG = percutaneous coronary 
intervention or coronary artery bypass grafting.
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REVISITING THE APPROACH TO PATIENTS WITH STABLE ISCHAEMIC SYMPTOMS
stem stenosis, underlying left-ventricular dysfunction and, in 
some cases, multivessel coronary artery disease. 
For the clinician having to deal with the individual patient and 
appreciating the modest benefits of percutaneous intervention, 
it will be important in future to consider whether these trial 
results are strictly applicable to the specific patient, what the 
severity or frequency of their angina is, whether there is evi-
dence of significant disease to warrant intervention, as well as 
taking into account the patient’s preference whether for initial 
medical therapy or revascularisation.
Building on the findings in these trials, an algorithm for managing 
chronic coronary syndrome is proposed (Figure 1). If symptoms 
suggest ischaemia, whether angina or dyspnoea, the patient 
should undergo risk factor and clinical assessment. Thereafter a 
functional test for ischaemia should be performed and inten-
sive guideline-directed optimal medical therapy commenced. If 
no ischaemia is detected, the patient should be investigated for 
an alternative cause of the symptoms. If ischaemia is demon-
strated, the patient should undergo CT coronary angiography 
to rule out left main stem stenosis which can be anticipated 
in about 5% of patients. Those found to have left main stem 
stenosis should be submitted to an invasive coronary angiogram 
and revascularised appropriately with either percutaneous 
intervention or coronary bypass surgery. Should there be no 
evidence of left main stem stenosis, it is safe to continue optimal 
medical therapy only and withhold invasive angiography until 
medical therapy is judged to have failed. Should the patient 
favour immediate intervention rather than optimal medical 
treatment, she/he should be fully informed of the equipoise in 
survival outcomes between the 2 options.
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